ABHD16A: A Potential Drug Target and Biomarker for Monoacylglycerol Lipase-Related Diseases

Target Name: ABHD16A

NCBI ID: G7920

ABHD16A

ABHD16A: A Potential Drug Target and Biomarker for Monoacylglycerol Lipase-Related Diseases

Abstract

Monoacylglycerol lipase (MAL) is a key enzyme involved in the metabolism of dietary lipids, and is often dysregulated in various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. The aim of this article is to review the literature on ABHD16A, a gene that has been identified as a potential drug target and biomarker for MAL-related diseases.

Introduction

Monoacylglycerol lipase (MAL) is an enzyme that is involved in the metabolism of dietary lipids, and is critical for the digestive process. MAL is a transmembrane protein that consists of 16 subunits, and its primary function is to catalyze the final step of the 灏?-oxidation process of lipid digestion, that is, triacylglycerols into low-energy lipids. MAL is regulated by various factors, including hormones, nutrients, and environmental factors.

In recent years, MAL has been linked to various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. Obesity is a major risk factor for MAL-related diseases, as it is associated with increased levels of MAL and its metabolite, 2, 2-dimethylpropion. MAL has also been shown to be involved in the regulation of energy metabolism and has been linked to the development of various metabolic disorders, including non-alcoholic fatty liver disease (NAFLD).

Drug Targets for MAL-Related Diseases

Several drugs have been developed to target MAL and its metabolites, with the goal of treating MAL-related diseases. One of the most well-known drugs is orlistat, which is a lipase inhibitor that reduces the amount of dietary lipids absorbed from the gut ( 5). Orlistat has been shown to reduce the levels of MAL and its metabolite in obese individuals and improve lipid profiles.

Another drug that targets MAL is ezetimibe, which is a inhibitor of the hepatic enzymes involved in MAL metabolism. Ezetimibe has been shown to reduce the levels of MAL and its metabolite in individuals with MAL-related diseases, including obesity and type 2 diabetes.

Biomarkers for MAL-Related Diseases

Monoacylglycerol lipase (MAL) is a key enzyme involved in the metabolism of dietary lipids and has been linked to various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. Therefore, the development of biomarkers for MAL-related diseases is of great interest . Several studies have shown that MAL and its metabolites can be used as biomarkers for various MAL-related diseases, including obesity and type 2 diabetes.

Monoacylglycerol lipase (MAL) gene has been identified as a potential drug target and biomarker for MAL-related diseases. Several studies have shown that MAL and its metabolites can be used as biomarkers for various MAL-related diseases, including obesity and type 2 diabetes.

Conclusion

In conclusion, ABHD16A is a gene that has been identified as a potential drug target and biomarker for monoacylglycerol lipase (MAL) -related diseases. The development of new treatments for MAL-related diseases is of great interest, and further research is needed to fully understand the role of ABHD16A as a drug target and biomarker.

Protein Name: Abhydrolase Domain Containing 16A, Phospholipase

Functions: Phosphatidylserine (PS) lipase that mediates the hydrolysis of phosphatidylserine to generate lysophosphatidylserine (LPS) (By similarity). LPS constitutes a class of signaling lipids that regulates immunological and neurological processes (By similarity). Has no activity towards diacylglycerol, triacylglycerol or lysophosphatidylserine lipase (PubMed:25290914). Also has monoacylglycerol lipase activity, with preference for 1-(9Z,12Z-octadecadienoyl)-glycerol (1-LG) and 2-glyceryl-15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ(2)-G) (PubMed:25290914)

The "ABHD16A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD16A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets